Cytokinetics Inc (CYTK)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012287
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases, which compromise muscle performance. The company’s lead drug candidate, tirasemtiv, a fast skeletal muscle troponin activator, is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis (ALS). Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase III clinical trials for heart failure. Its other pipeline products include CK-2127107 for the treatment spinal muscular atrophy and chronic obstructive pulmonary disease. It has licensing agreements with Amgen and Astellas for the development of its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Astellas Pharma Expands Licensing Agreement with Cytokinetics 10
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 12
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor 14
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 15
Equity Offering 17
Cytokinetics Plans to Raise Funds through Public Offering of Securities 17
Cytokinetics Prices Public Offering of Shares for USD75 Million 18
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 20
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 21
Cytokinetics Completes Public Offering Of Shares For US$5 Million 23
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 24
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 26
Cytokinetics Completes Private Placement Of Common Stock For US$8 Million 28
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For US$12.1 Million 30
Cytokinetics Inc – Key Competitors 32
Cytokinetics Inc – Key Employees 33
Cytokinetics Inc – Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Strategy And Business Planning 35
Jan 11, 2016: Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug Candidates 35
Financial Announcements 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 36
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 38
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 40
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 42
Oct 27, 2016: Cytokinetics Reports Third Quarter 2016 Financial Results 45
Jul 28, 2016: Cytokinetics Reports Second Quarter 2016 Financial Results 48
Apr 28, 2016: Cytokinetics Reports First Quarter 2016 Financial Results 50
Feb 16, 2016: Cytokinetics Reports Fourth Quarter 2015 Financial Results 52
Corporate Communications 55
May 20, 2016: Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors 55
Product News 56
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 56
Clinical Trials 57
Nov 07, 2016: Cytokinetics Announces Publication Relating to Novel Smooth Muscle Myosin Inhibitor 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cytokinetics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Astellas Pharma Expands Licensing Agreement with Cytokinetics 10
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 12
Cytokinetics Enters Into Licensing Agreement With MyoKardia For Cardiac Sarcomere Inhibitor 14
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 17
Cytokinetics Prices Public Offering of Shares for USD75 Million 18
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 20
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 21
Cytokinetics Completes Public Offering Of Shares For US$5 Million 23
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 24
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 26
Cytokinetics Completes Private Placement Of Common Stock For US$8 Million 28
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For US$12.1 Million 30
Cytokinetics Inc, Key Competitors 32
Cytokinetics Inc, Key Employees 33

★海外企業調査レポート[Cytokinetics Inc (CYTK)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sarawak Energy Bhd:企業の戦略的SWOT分析
    Sarawak Energy Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Prinzhorn Holding Gmbh
    Prinzhorn Holding Gmbh - Strategy, SWOT and Corporate Finance Report Summary Prinzhorn Holding Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Norwegian Energy Company ASA:企業のM&A・事業提携・投資動向
    Norwegian Energy Company ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Norwegian Energy Company ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Velvet Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Velvet Energy Ltd (Velvet Energy) is an oil and gas exploration company that explores and develops oil and liquid-rich natural gas from its assets. The company’s exploration and development operation assets are located in Deep Basin in West-Central Alberta. It produces 17,000 barrels of oil …
  • Empire Electric Association Inc:企業の戦略的SWOT分析
    Empire Electric Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Symbiotec Pharmalab Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • Insmed Inc (INSM):医療機器:M&Aディール及び事業提携情報
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are bein …
  • W. L. Gore & Associates, Inc.:企業の戦略・SWOT・財務情報
    W. L. Gore & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary W. L. Gore & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Cooper Tire & Rubber Company:企業の戦略・SWOT・財務情報
    Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report Summary Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Gfk SE (GFK):企業の財務・戦略的SWOT分析
    Summary Gfk SE (GfK) is a business service provider that offers market and consumer services. The company provides solutions such as online pricing intelligence, brand and customer experience, point of sales analytics, digital marketing intelligence, consumer panels, product catalogs, market opportu …
  • Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析
    Summary Strongbridge Biopharma plc (Strongbridge), formerly Cortendo plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokale …
  • ALSTOM SA:企業の戦略・SWOT・財務分析
    ALSTOM SA - Strategy, SWOT and Corporate Finance Report Summary ALSTOM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Denver Water:企業の戦略的SWOT分析
    Denver Water - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Miltenyi Biotec GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company that offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company offers sample preparation, cell separation, flow cytometry, cell culture and stimulati …
  • Stanley Black & Decker Inc:戦略・SWOT・企業財務分析
    Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report Summary Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Kforce Inc (KFRC):企業の財務・戦略的SWOT分析
    Kforce Inc (KFRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pall Corp-医療機器分野:企業M&A・提携分析
    Summary Pall Corp (Pall), a subsidiary of Danaher Corporation, is a supplier of filtration, separation and purification products and technologies to remove solid, liquid and gaseous contaminants from liquids and gases. Its major products include biochemicals, bioreactors, breathers, canisters, cartr …
  • Hemispherx Biopharma Inc (HEB):医療機器:M&Aディール及び事業提携情報
    Summary Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chro …
  • Siemens AG (SIE):企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Owens & Minor Inc (OMI):企業の財務・戦略的SWOT分析
    Owens & Minor Inc (OMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆